Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Laquinimod Meets Primary Endpoint In First Phase III Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Favorable safety profile may differentiate Teva's laquinimod from competing oral multiple sclerosis therapies.

You may also be interested in...



Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO

Teva's application to join the Biotechnology Industry Organization may say as much about BIO as it does about the firm.

Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO

Teva's application to join the Biotechnology Industry Organization may say as much about BIO as it does about the firm.

Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015

Despite a string of uncharacteristic setbacks, Teva remains confident in its long-term strategy and five-year financial goals it outlined a year ago.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel